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Posttranscriptional regulatory mechanisms superim-
pose ‘‘fine-tuning’’ control upon ‘‘on-off’’ switches
characteristic of gene transcription. We have ex-
ploited computational modeling with experimental
validation to resolve an anomalous relationship
between mRNA expression and protein synthesis.
The GAIT (gamma-interferon-activated inhibitor of
translation) complex repressed VEGF-A synthesis
to a low, constant rate independent of VEGF-A
mRNA expression levels. Dynamic model simula-
tions predicted an inhibitory GAIT-element-interact-
ing factor to account for this relationship and led to
the identification of a truncated form of glutamyl-
prolyl tRNA synthetase (EPRS), a GAIT constituent
that mediates binding to target transcripts. The trun-
cated protein, EPRSN1, shields GAIT-element-
bearing transcripts from the inhibitory GAIT complex,
thereby dictating a ‘‘translational trickle’’ of GAIT
target proteins. EPRSN1mRNA is generated by poly-
adenylation-directed conversion of a Tyr codon in
the EPRS-coding sequence to a stop codon (PAY*).
Genome-wide analysis revealed multiple candidate
PAY* targets, including the authenticated target
RRM1, suggesting a general mechanism for produc-
tion of C terminus-truncated regulatory proteins.INTRODUCTION
The human genome encodes about 25,000 mRNAs that repre-
sent a lower bound of the expressed proteome in eukaryotic88 Cell 149, 88–100, March 30, 2012 ª2012 Elsevier Inc.organisms due to expansion fromupstreamopen reading frames
(ORFs), alternative splicing, alternative polyadenylation, post-
translational modification, and proteolysis. Alternative protein
forms can acquire completely distinct activities but more
commonly exhibit a function related to the parental forms. One
major protein family featuring a plethora of alternative structures
and functions are the eukaryotic aminoacyl-tRNA synthetases
(AARS). AARS are constitutive ‘‘house-keeping’’ enzymes, ubiq-
uitous in the three kingdoms of life, and required for activation
of cognate amino acids for interpretation of the genetic code
(Ibba and So¨ll, 2000; Ribas de Pouplana and Schimmel, 2001).
In addition to this ancient function, newly evolved noncanonical
functions of multiple metazoan AARS depend on domains
recently (in terms of evolutionary time) appended to the enzyme
catalytic cores (Guo et al., 2010; Park et al., 2008). In previous
studies of translational control of gene expression, we have
shown that the bifunctional AARS glutamyl-prolyl tRNA synthe-
tase (EPRS) exhibits an additional noncanonical function that is
similarly dependent on a metazoa-specific appended domain
(Mukhopadhyay et al., 2009; Ray et al., 2011).
IFN-g treatment of myeloid cells robustly induces cerulo-
plasmin (Cp) and vascular endothelial growth factor-A (VEGF-A)
mRNAs. However, synthesis of the proteins stops almost
completely about 14–16 hr after IFN-g treatment, despite undi-
minished mRNA level (Mazumder and Fox, 1999; Ray and Fox,
2007). Translational silencing requires binding of the GAIT
(gamma-interferon-activated inhibitor of translation) complex,
consisting of EPRS as well as ribosomal protein L13a, NS1-
associated protein 1 (NSAP1), and glyceraldehyde 3-phosphate
dehydrogenase (GAPDH), to structural elements in the target
mRNA 30 untranslated regions (UTRs) (Mazumder and Fox,
1999; Sampath et al., 2003) (Figure 1A). GAIT complex assembly
is driven by IFN-g-inducible phosphorylation of EPRS and L13a
and consequent release from their parent macromolecular com-
plexes, notably the aminoacyl-tRNA multisynthetase complex
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Figure 1. Differential Regulation of VEGF-A mRNA
and Protein by the GAIT Pathway
(A) Schematic of GAIT pathway of transcript-selective
translational control.
(B) IFN-g-stimulated monocytic cells maintain low-level
expression of VEGF-A. U937 cells were treated with IFN-g
at up to 500 U/ml for 8 (left) or 24 (right) hr. VEGF-A mRNA
was determined by qRT-PCR (top), and VEGF-A protein
and b-actin in cell lysates by immunoblot analysis (middle
panels). VEGF-A protein as function of VEGF-A mRNA is
shown (mean ± standard error of the mean [SEM], n = 3)
(bottom).(MSC) (Arif et al., 2009, 2011; Sampath et al., 2004) and the large
ribosomal subunit, respectively (Mazumder et al., 2003; Mukho-
padhyay et al., 2008). Assembly occurs in two stages. During
the first 2 hr period, phospho-EPRSbindsNSAP1 to forman inac-
tive, pre-GAIT complex that does not bind GAIT-bearing target
mRNA. About 12–14 hr later, phospho-L13a and GAPDH join
thepre-GAITcomplex to form theheterotetramericGAITcomplex
that binds the 30 UTR GAIT element of target mRNAs and blocks
translation initiation (Kapasi et al., 2007; Mazumder et al., 2001).
EPRS has a special role in GAIT-mediated translational
control, as it is solely responsible for recognition and interaction
with GAIT elements in target mRNAs (Ray et al., 2009; Sampath
et al., 2004). Metazoan EPRS is the only bifunctional AARS andCell 14catalyzes Glu and Pro ligation to cognate tRNAs
(Ray et al., 2011). Human EPRS is a 172 kDa,
1512 amino acid polypeptide consisting of three
major domains. The N and C termini contain ERS
and PRS catalytic domains, respectively, joined
by a 300 amino acid linker containing three
tandem WHEP-TRS (referred to as WHEP)
domains. The WHEP domain is a 50 amino acid
helix-turn-helix structure (Cahuzac et al., 2000;
Jeong et al., 2000) named after the AARS con-
taining them, i.e., WRS, HRS, and EPRS. The
upstream WHEP repeat pair is essential for
high-affinity binding to the GAIT RNA element,
whereas the overlapping, downstream pair (and
adjacent spacers) contains the phosphorylation
sites essential for GAIT complex assembly (Jia
et al., 2008).
L13a phosphorylation is a critical event deter-
mining the timing of GAIT system activation
(Figure 1A). IFN-g induces L13a phosphorylation
by activation of a kinase cascade in which death-
associated protein kinase-1 (DAPK) activates
the proximal kinase zipper-interacting protein
kinase (ZIPK) (Mukhopadhyay et al., 2008).
DAPK and ZIPK mRNAs contain functional 30
UTR GAIT elements, and thus the inhibitory
pathway activated by the kinases also sup-
presses their expression. Delayed feedback inhi-
bition of DAPK and ZIPK restores the cell to the
basal state and allows GAIT system reactivation
by subsequent stimulation.Here we exploit a dynamic modeling approach to understand
the mechanism underlying a marked discrepancy in expression
of GAIT system targets. Activation of monocytic cells for 24 hr
by a wide range of concentrations of IFN-g induces an equally
broad range of expression of VEGF-AmRNA; however, differen-
tial mRNA expression does not correspond to differential protein
expression but rather to a constant, low-level ‘‘trickle’’ of
synthesis of VEGF-A protein. Mathematical modeling of the
known features of the GAIT system failed to replicate these
observations. But the addition of a putative GAIT-element-inter-
acting factor (GEIF) to the model permitted a successful fit. The
modeling was validated by discovery of a novel truncated EPRS
mRNA and protein responsible for the observed aberrant9, 88–100, March 30, 2012 ª2012 Elsevier Inc. 89
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Figure 2. Dynamic Modeling of GAIT System Indi-
cates that GEIF Is Responsible for the Transla-
tional Trickle of VEGF-A Expression
(A) Dynamic modeling of GAIT system. Keymodel features
are as follows: Gi, inactive (or unformed) GAIT complex; G,
active GAIT complex; M, GAIT-element-bearing mRNA;
GM, GAIT complex-bound mRNA; P, newly synthesized
GAIT target protein. Dashed compartment contains the
following: F, GEIF; FM, GEIF-bound mRNA. Rate con-
stants are indicated within triangles.
(B) Model simulations without GEIF. Rate of protein
synthesis versus total mRNA before (8 hr) and after (24 hr)
translational silencing using the initial model without GEIF
(dashed lines); model simulations were done for a range of
IFN-g concentrations (left). Model simulations are with
best-fit ratio of GAIT complex to target mRNA (ratio = 15)
as determined by nonlinear regression (right).
(C) Model simulationswith GEIF. Simulations (dashed lines
and curves) in presence of GEIF are based on experi-
mentally determined parameters (left) and in presence of
a 2-fold higher or 75% lower amount of GEIF (right).
See also Figure S1 and Tables S1 and S2.relationship between VEGF-A mRNA and protein expression.
Moreover, we have elucidated an RNA-processing mechanism
that generates the truncated EPRS mRNA and protein and
contributes to transcriptome expansion.
RESULTS
Dynamic Modeling of GAIT System Predicts
a GAIT-Element-Interacting Factor
During investigation of GAIT response dynamics, a dose-
response experiment revealed an unexpected result. U937
monocytic cells were treated with a broad range of concentra-
tions of IFN-g for 8 hr, a time before induction of GAIT-mediated
silencing activity, and for 24 hr, when GAIT silencing activity is in90 Cell 149, 88–100, March 30, 2012 ª2012 Elsevier Inc.effect. At 8 hr, an increase in IFN-g was associ-
ated with an increase of both VEGF-A mRNA
and lysate protein (a relative measure of the
rate of synthesis of the secreted protein) (Fig-
ure 1B, left), and a near-linear relationship
between VEGF-A mRNA and protein synthesis
was observed. In contrast, at 24 hr, VEGF-A
protein was expressed at a low, near-constant
amount over a wide range of IFN-g treatment
that was independent of the high, variable
VEGF-A mRNA expression (Figure 1B, right).
To understand the mechanism underlying this
‘‘translational trickle’’ of GAIT target protein
expression observed at 24 hr, an initial mathe-
matical model of the system dynamics contain-
ing the key components that regulate gene
expression was developed. This mechanism-
based model included delayed activation of
the GAIT complex after 14 hr and feedback inhi-
bition of DAPK and ZIPK after 32 hr (Figure 2A,
without dashed compartment and vectors).
Complete model details, initial conditions (TableS1 available online), and parameters (Table S2) are described in
Modeling Procedures in the Extended Experimental Procedures.
The maximum amount of GAIT complex formed was determined
by the amount of free L13a in cells treated with IFN-g for 24 hr,
previously shown to be about 95% of total L13a (Mazumder
et al., 2003). Total GAIT-element-bearing target mRNA under
the same condition was approximated by RNA immunoprecipi-
tation (RIP) with anti-EPRS antibody. The ratio of GAIT complex
to total target mRNA is about 50–100 in U937 cells, and the
upper limit value of 100 was used for model simulation. The
kinetics and dose response of VEGF-A mRNA and protein
following IFN-g stimulation were taken as representative of
GAIT targets as a whole. The model rate equations were repre-
sented by ordinary differential equations, and simulated results
were compared to the experimental measurements. The simula-
tion gave a linear relationship between target protein synthesis
rate and mRNA at both 8 and 24 hr; moreover, protein synthesis
at 24 hr was repressed almost completely (Figure 2B, left). When
the ratio of GAIT complex to target mRNA was varied (to influ-
ence the extent of silencing), the model still could not simulate
the experimental nonlinear relationship between total mRNA
and protein synthesis rate. The best-fit value for the GAIT
complex-to-target mRNA ratio was calculated by least-squares
fitting of the model output to the experimental data. Although the
fit was improved, the model failed to predict the observed
nonlinear relationship between VEGF-A mRNA and protein
synthesis rate (Figure 2B, right).
We considered the potential role of a GAIT complex inhibitor
that sequesters the complex from target mRNAs, but this model
also generated a linear relationship between VEGF-A mRNA and
protein synthesis rate at 24 hr (Figures S1A–S1D). Likewise,
a model featuring two inducible pools of mRNA with and without
the GAIT element failed to simulate the nonlinear relationship
(Figures S1E and S1F). Finally, we considered the possibility of
a GEIF that binds GAIT-element-bearing mRNAs and prevents
their interaction with the GAIT complex while permitting transla-
tion (Figure 2A, with dashed compartment and vectors). Upon
inclusion of GEIF in an enhanced model, simulation produced
the experimentally observed nonlinear relationship between
protein synthesis rate and mRNA at 24 hr, although maintaining
the linear relationship at 8 hr (Figure 2C, left). The species
dynamics indicate the distribution of GAIT-element-bearing
mRNAs between the GAIT complex-bound, GEIF-bound, and
unbound forms (Figure S1G). The small amount of GEIF-bound,
protected mRNA directs a constant ‘‘translational trickle’’ at
24 hr. Nonlinear regression of the experimental data with the
GEIF-containing model gave estimates of stoichiometry and
dissociation constant of this putative binding factor (Table S2).
We compared the squared residual (deviation of simulated
protein synthesis rate from the experimental measurement) for
various IFN-g0 inputs for several models. The best-fitting model,
as indicated by the minimum value of the sum of squared resid-
uals, was obtained for the enhanced model with GEIF (Fig-
ure S1H). A p value > 0.05 indicates no statistical difference
between the model and experimental outputs, i.e., a goodmodel
fit. The enhanced model with GEIF (p = 0.23) satisfied this crite-
rion, whereas the best-fit model without GEIF (p = 0.002) did not
(see Extended Experimental Procedures for details). Increasing
the amount of GEIF in the model increased the steady-state
trickle level, whereas decreasing GEIF had the opposite effect
(Figure 2C, right).
Discovery of a Truncated EPRS Variant Containing Only
the Upstream WHEP Domain Pair that Binds the GAIT
Element
To determine the nature of the putative GEIF, i.e., RNA or protein,
we examinedwhether expression of a secondGAITmRNA target
exhibits similar dynamic characteristics. ZIPK mRNA contains
a GAIT element with a predicted secondary structure similar to
that of VEGF-A mRNA but with a completely unrelated primary
sequence (Mukhopadhyay et al., 2008). U937 cells were treated
with IFN-g for 8 and 24 hr and ZIPK mRNA determined byRT-PCR and protein synthesis by [35S]methionine labeling fol-
lowed by immunoprecipitation. The relationship between ZIPK
mRNA expression and protein synthesis was similar to that
observed for VEGF-A (Figure 3A). The experimentally deter-
mined GAIT elements of VEGF-A and ZIPK have completely
different mRNA sequences but nearly identical calculated
secondary structures (Mukhopadhyay et al., 2008; Ray and
Fox, 2007). Thus the putative factor responsible for binding
both elements is unlikely to be a sequence-specific microRNA
(or other noncoding RNA) but rather an RNA-binding protein
that recognizes the GAIT structural element common to all
GAIT target mRNAs. Moreover, these results suggest that
GEIF-directed relief of translational silencing might represent
an additional layer of posttranscriptional regulation of the GAIT
regulon.
To explore experimentally the presence of a GEIF, we consid-
ered previous studies showing that the upstream pair of WHEP
domains in the EPRS linker is sufficient for high-affinity binding
to the GAIT RNA element but does not contain the phosphoryla-
tion sites required for interaction with GAIT constituents (Arif
et al., 2009; Jia et al., 2008). These findings suggest that a minor
EPRS variant containing only the upstream pair of WHEP
domains might be responsible for the observed trickle phenom-
enon. An approximately 95 kDa EPRS variant was detected in
lysates from human monocytic U937 cells (Figure 3B) and from
primary human peripheral blood monocytes (PBM, Figure 3C)
by immunoblot with antibody against the EPRS linker domain.
Anti-N-terminus antibody also detected both proteins, but
PRS-specific antibody recognized only full-length EPRS. The N
terminus-containing truncated form (designated EPRSN1) was
analyzed by mass spectrometry following immunoprecipitation
with anti-linker antibody and SDS-PAGE. Peptide coverage
spanned ERS and the first two of three WHEP repeats in the
linker domain (Figure 3D).
To investigate the mechanism underlying expression of
truncated EPRS, total RNA from U937 cells was subjected to
northern analysis with region-specific cDNA probes. Major
5.5 kb andminor 3 kb bands were detected with an ERS-specific
probe, but the smaller band was not detected by a PRS-specific
probe, suggesting transcript-directed synthesis of EPRSN1 (Fig-
ure 4A). IFN-g, which induces EPRS phosphorylation and release
from the MSC (Arif et al., 2009), did not alter the amount of either
transcript. Cytosolic lysates were fractionated on a sucrose
gradient, and total RNA from each fraction was subjected to
northern analysis with an ERS-specific probe. Both full-length
EPRS and EPRSN1mRNAs were primarily found in the polysome
fractions, indicating efficient translation (Figure 4B). Following
G/I tailing (i.e., addition of polyG/I tails to total RNA) and RT-PCR,
agarose gel electrophoresis detected polyadenylated products
up to about 400 nt (Figure 4C, left). Sequencing of the 200 nt
fraction revealed a cDNA identical to the N terminus of EPRS
up to Tyr864-encoding UAU, which is replaced by a UAA stop
codon followed by a poly(A) tail without an intervening 30 UTR
(Figure 4C, right). EPRSN1 mRNA encodes ERS, WHEP R1,
and the a helices of WHEP R2, but not the last 12 amino acids
of R2. The region containing R1 and R2 binds GAIT-element
RNA, whereas the linker region downstream of R2 contains
IFN-g-dependent phosphorylation sites required both for GAITCell 149, 88–100, March 30, 2012 ª2012 Elsevier Inc. 91
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Figure 3. Monocytic Cells Contain a C-Terminal
Truncated EPRS, EPRSN1
(A) IFN-g-stimulated monocytic cells maintain low-level
synthesis of ZIPK. U937 cells were treated with IFN-g as in
Figure 1B. ZIPKmRNA was determined by qRT-PCR (top),
and ZIPK synthesis determined by metabolic labeling with
[35S]Met followed by immunoprecipitation (IP) with anti-
ZIPK antibody (middle). ZIPK protein synthesis as function
of ZIPK mRNA is shown (mean ± SEM, n = 3) (bottom).
(B) Detection of EPRSN1 protein in U937 cells with domain-
specific antibodies. Cytosolic lysates from U937 cells were
subjected to immunoblot analysis with antibodies directed
against EPRS linker domain, EPRSN-terminal peptide, and
PRS.
(C) Presence of EPRSN1 in human PBM. Immunoblot
analysis with antibodies directed against the EPRS linker
and PRS domains.
(D) Mass spectrometric analysis indicates that EPRSN1
contains ERS, R1, and R2 domains but lacks R3 and PRS
domains. EPRSN1 was isolated by immunoprecipitation
with anti-EPRS linker antibody and SDS-PAGE and de-
tected with Coomassie stain (left). Peptides detected by
mass spectrometric analysis of a 95 kDa EPRSN1 band
(red) and WHEP domains (underlined) are shown (right).complex assembly and for GAIT function (Arif et al., 2009; Jia
et al., 2008) (Figure 4D).
EPRSN1 Is Responsible for the Translational Trickle
To determinewhether EPRSN1, like EPRS, resides in theMSCand
is released upon stimulation, U937 cells were transfected with
c-Myc-tagged EPRSN1 and incubated with IFN-g for up to 24 hr.
The MSC was collected by immunoprecipitation with antibody
against KRS, an MSC constituent. As shown before, full-length
EPRS is present in the MSC and released upon IFN-g treatment;
however, EPRSN1 is not detected in the MSC (Figure 5A). The
pre-GAIT and GAIT complexes were collected by immunoprecip-
itation with anti-NSAP1 antibody. As shown previously, IFN-g
induces translocationof full-lengthEPRS to thepre-GAITcomplex
(at 2 hr), where it is joined by other components to form themature
GAIT complex (at 14 hr), but neither complex contains EPRSN1.
The inability to bind NSAP1 confirms that EPRSN1 does not form
the functional, heterotetrameric GAIT complex.92 Cell 149, 88–100, March 30, 2012 ª2012 Elsevier Inc.Based on the predicted binding activities, we
considered that EPRSN1 might act as a domi-
nant-negative inhibitor of the translational
silencing activity directed by full-length EPRS.
The interaction of EPRSN1 with GAIT-element
RNA was determined by surface plasmon
resonance (SPR) spectrometry. Recombinant
EPRSN1 bound Cp GAIT-element RNA with a
dissociation constant (KD) of about 0.37 nM,
whereas full-length EPRS bound with a KD about
30-fold higher (Figure 5B). The high binding
affinity of EPRSN1 was primarily due to a very
low off-rate and suggests that EPRSN1 can
effectively compete with GAIT complex for
binding target mRNAs. EPRSN1 binding to inac-
tive, mutant (U87C) Cp GAIT-element RNA wasbelow the detection limit (not shown). To investigate binding
in vivo, EPRSN1-c-Myc was transfected into cells and immuno-
precipitated with anti-c-Myc antibody, and bound RNA was de-
tected by RT-PCR with mRNA-specific primers. Ectopically
expressed EPRSN1 exhibited robust binding to VEGF-A but not
b-actin mRNA, demonstrating specific interaction in cells as
shown by RT-PCR (Figure 5C) and more quantitatively by qRT-
PCR (Figure S2A). To determine its inhibitory activity, EPRSN1
was overexpressed in cells, and the interaction of the GAIT
complex constituent L13a with VEGF-A mRNA was measured
by RNA immuonprecipitation with anti-L13a antibody. Indeed,
ectopic expression of EPRSN1 blocked L13a binding to VEGF-A
mRNA, indicating effective competition, as shown by RT-PCR
(Figure 5D) and qRT-PCR (Figure S2B).
To investigate the influence of EPRSN1 on GAIT target gene
expression, we determined the effect of recombinant, His-
tagged EPRSN1 on in vitro translation of a reporter RNA. VEGF-A
GAIT-element-bearing firefly luciferase (FLuc) and renilla
AB
C
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Figure 4. Monocytic Cells Express EPRSN1 mRNA
(A) EPRSN1 mRNA is expressed constitutively. Total RNA from U937 cells
treated with IFN-g was subjected to RNA blot analysis using ERS- and PRS-
specific probes.
(B) EPRSN1 mRNA is translatable. U937 cell lysates were fractionated on
a sucrose gradient, and extracted RNA in each fraction was subjected to RNA
blot analysis with ERS-specific probe.
(C) Nucleotide sequence of EPRSN1 mRNA. G/I stretches were added to
poly(A)-tailed mRNA, RT-PCR was done using oligo-C and gene-specific
upstream primers, and the amplified fragment was cloned into T-vector and
sequenced.
(D) Schematic of EPRSN1 structure in context of full-length EPRS, its phos-
phorylation sites, and its binding partners.luciferase (RLuc) control RNAs were cotranslated in rabbit retic-
ulocyte lysate (RRL) in the presence of cytosolic lysate from
IFN-g-treated cells. As shown previously, 24 hr lysate specifi-
cally inhibited translation of GAIT-element-bearing mRNA (Jia
et al., 2008); however, EPRSN1 almost completely restored
expression (Figure 5E). To determine the mechanism of transla-
tional inhibition, lysates from c-Myc-tagged EPRSN1-trans-
fected, IFN-g-treated cells were fractionated on a sucrose
gradient, and VEGF-A mRNA was determined by RT-PCR. A
near-complete shift of VEGF-A mRNA from a translationally
silent mRNP pool to the translationally active polysome fractions
indicated that EPRSN1 prevents GAIT complex-mediated inhibi-
tion of target mRNA translation (Figure 5F). To show that EPRSN1
affects endogenous gene expression, transfected U937 cells
were treated with IFN-g, and VEGF-A and Cp expression
measured by immunoblot. Overexpression of EPRSN1 markedly
increased in vivo expression of GAIT target proteins after 24 hr
IFN-g treatment compared to transfection controls (Figure 5G,
left). VEGF-A mRNA expression was not significantly increased
by ectopic expression of EPRSN1 (Figure 5G, right). The nearly
2-fold increase in Cp mRNA is expected to have a small effect
on protein expression, as shown by an undetectable increase
in protein following 4- to 8-fold increases in VEGF-A or ZIPK
mRNA, respectively (Figures 1B and 3A), and certainly cannot
account for the observed 5-fold increase in Cp protein expres-
sion. These experiments demonstrate that EPRSN1, by high-
affinity binding to GAIT target mRNAs, protects a small amount
of mRNA from GAIT complex-mediated translational silencing,
thereby maintaining low-level expression of target protein
despite high-level induction of mRNA. Thus, EPRSN1 is the
GEIF predicted by the modeling studies described above.
EPRSN1 Is Generated by Polyadenylation-Mediated
Tyr-to-Stop Codon Conversion
Analysis of human genome sequence databases did not reveal
a duplicated EPRS gene. Moreover, the substitution of a Tyr-en-
coding UAU codon in EPRS mRNA with a UAA stop codon
followed by poly(A) in EPRSN1 mRNA was not consistent with
an alternative splicingmechanism.We considered the possibility
that EPRSN1 mRNA might be generated by an alternative polya-
denylation (APA) eventwithin theEPRSmRNAcoding region that
recodes a Tyr codon to a stop. Polyadenylation generally utilizes
a C/UA cleavage site, an upstream hexanucleotide element
(AAUAAA) or its variant (AUUAAA), and a downstream U- or
GU-rich element, although these requirements are not absolute
(Birnstiel et al., 1985). Inspection of EPRS mRNA sequence
near the EPRSN1 30 terminus revealed a UA cleavage site within
the terminal Tyr codon, a consensus upstream hexanucleotide
element at 40 (relative to the cleavage site), and a downstream
U-rich element at +117 (Figure 6A). To provide evidence for
polyadenylation-mediated Tyr-to-stop codon conversion
(PAY*) and verify the cis-acting signal elements, we subjected
a [32P]UTP-labeled polyadenylation cassette to an in vitro
cleavage assay (Ahmed et al., 1991; Bar-Shira et al., 1991;
Hans and Alwine, 2000; Wu and Alwine, 2004). The 240 nt APA
cassette RNA, containing the cleavage site and putative
upstream and downstream elements, was cleaved into a 109
nt 50 RNA product by nuclear extract from U937 cells (Figure 6B).Cell 149, 88–100, March 30, 2012 ª2012 Elsevier Inc. 93
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Figure 5. EPRSN1 Binding to GAIT-Element RNA Blocks Translational Repression
(A) EPRSN1existsasa freeproteinoutside theMSCorGAITcomplex.U937cellswere transfectedwithpcDNA3.1-EPRSN1-Mycplasmidand treatedwith IFN-g for upto
24hr.Cell lysateswere immunoprecipitatedwithanti-KRSandanti-NSAP1antibodies, thensubjectedto immunoblotwithanti-EPRS linkerandanti-Myc tagantibodies.
(B) High-affinity binding of EPRSN1 to GAIT RNA element. Biotinylated, 29 nt Cp GAIT-element RNA was immobilized on a streptavidin sensor chip. Binding of
human EPRSN1 (left) and full-length rat EPRS (right) was determined by SPR and expressed as RU.
(C) EPRSN1 interacts with VEGF-A mRNA in vivo. U937 cells were transfected with pcDNA3.1-EPRSN1-Myc or Myc vector control, and lysates immunopre-
cipitated (IP) with anti-Myc antibody. Extracted RNA was subjected to RT-PCR using primers specific for VEGF-A or b-actin mRNA.
(D) EPRSN1 inhibits GAIT complex binding to VEGF-A mRNA. U937 cells were transfected with pcDNA3.1-EPRSN1-Myc or vector control, and GAIT complex in
lysates was immunoprecipitated with anti-L13a antibody. Extracted RNA was subjected to RT-PCR as in (C).
(E)RecombinantEPRSN1 restores in vitro translationof theGAIT-element-bearing reporter. In vitro translationof theFLuc reporterbearing theVEGF-AGAITelement
(and RLuc control RNA) was determined in a rabbit reticulocyte lysate (RRL) in the presence of [35S]Met, cytosolic extracts from IFN-g-treated U937 cells, and
recombinant EPRSN1. FLuc expression was quantitated by densitometry, normalized by RLuc expression, and reported asmean ± standard deviation (SD) (n = 3).
(F) EPRSN1 restores translation of endogenous GAIT-element-bearing mRNAs. Lysates from U937 cells transfected with pcDNA3.1-EPRSN1-Myc were frac-
tionated on a sucrose gradient, and total RNA subjected to RT-PCR with VEGF-A- and GAPDH-specific primers.
(G) EPRSN1 restores expression of GAIT-element-bearing mRNAs. U937 cells were transfected with pcDNA3.1-EPRSN1-Myc and treated with IFN-g for up to
24 hr. Cell lysates were subjected to immunoblot (left) and qRT-PCR (right) analyses as shown. The relative VEGF-A andCpmRNA levels were reported asmean ±
SEM (n = 3).
See also Figure S2.
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Mutation of the UA cleavage site or the upstream or downstream
elements prevented cleavage, as did immunodepletion of cleav-
age and polyadenylation stimulation factor-100 (CPSF100).
In vitro polyadenylation of the precleaved RNA cassette likewise
was consistent with the in vitro cleavage results (Figure 6C).
To investigate the role of the PAY* mechanism in vivo, a
reporter plasmid was generated by subcloning the polyadenyla-
tion cassette downstream of the RLuc coding region to replace
the SV40 late cassette in the pRL-SV40 plasmid. This assay is
based on the requirement for transcript polyadenylation for
efficient translation (McMahon et al., 2006). The reporter was
cotransfected with a plasmid encoding FLuc as a control for
transfection efficiency. The wild-type cassette was expressed
much more efficiently than either the upstream or downstream
mutants, consistent with in-CDS (in-coding sequence) APA in
cells (Figure 6D). To verify the activity of endogenous EPRSN1,
U937 cells (Figure 6E) and human PBM (Figure S3A) were trans-
fected with antisense morpholino oligomer targeting the alterna-
tive cleavage site. The morpholino reduced EPRSN1 expression
by about 75% and concomitantly reduced the VEGF-A trickle
level by about the same amount (Figure 6E), consistent with
the simulation results (Figure 2C, right, 0.253 GEIF). These
data support the PAY* mechanism and verify that EPRSN1 is
responsible for maintaining the translational trickle of VEGF-A
expression.
Transcriptome Expansion by the PAY* Mechanism
We used a bioinformatic approach to globally seek candidate
mRNAs generated by PAY*. The human expressed sequence
tag (EST) and mRNA databases were queried with two criteria:
(1) coding RNA has a poly(A) tail immediately downstream of
the first UAA stop codon, and (2) the UAA stop codon replaces
a Tyr-encoding UAU or UAC in a larger transcript that extends
30 beyond the truncated mRNA (Figures S3B and S3C). Seven
candidate transcripts fulfilling both criteria were identified;
among them only ribonucleotide reductase M1 (RRM1), an
important cancer marker gene, exhibited a perfect consensus
upstream element (at position 18) within the same exon as
the cleavage site (Figure S3D). Two-round nested RT-PCR of
U937 cell RNA revealed the truncated form of RRM1 (RRM1N1)
(Figure 6F). We cannot exclude the possibility that other candi-
date truncated mRNAs might be found in other cell types or
under other conditions. RNA blot analysis with 50- and 30-specific
RRM1 probes verified the presence of the C-terminal truncated
form (Figure 6G). Sucrose gradient fractionation of cell lysate fol-
lowed by northern analysis with an N terminus-specific RRM1
probe confirmed low-level expression of RRM1N1 (compared
to the full-length mRNA) and also showed strong association
with polysomes indicative of active translation (Figure 6H).
Immunoblot analysis of cell lysates with antibodies generated
against the N and C termini of RRM1 confirmed the presence
of both full-length RRM1 and RRM1N1 in human PBM (data not
shown) and U937 cells (Figure 6I).
DISCUSSION
Dynamic modeling of the GAIT system, coupled with experi-
mental validation, revealed two EPRS isoforms, a full-lengthform residing in the MSC and GAIT complex and a truncated
free form, ERPSN1. ERPSN1 performs a function closely related
to the noncanonical function of the parental form, namely,
acting as a dominant-negative inhibitor that prevents complete
translational silencing of target transcripts by the GAIT complex.
Thus EPRS joins a select group of AARS that exhibit a nonca-
nonical activity requiring a truncation event that reveals a cryptic
stimulatory domain or removes an inhibitory peptide. For
example, proteolytic removal of the EMAPII domain from YRS
unmasks a tripeptide motif that confers proangiogenic activity
(Wakasugi and Schimmel, 1999). Likewise, deletion of a
WHEP domain from WRS by proteolysis or alternative splicing
generates an antiangiogenic protein (Wakasugi et al., 2002).
RRS exhibits two isoforms produced by alternative translation
initiation from a single mRNA; the larger isoform resides in the
MSC, whereas the smaller isoform is free (Kyriacou and
Deutscher, 2008).
ERPSN1 is constitutively generated by an unanticipated PAY*
mechanism within the coding region of EPRS. APA generally
occurs in noncoding regions of mRNAs, most often distal to
the stop codon generatingmRNAswith a shorter 30 UTR, thereby
eliminating sites of posttranscriptional regulation (Danckwardt
et al., 2008; Edwalds-Gilbert et al., 1997; Licatalosi and Darnell,
2010; Millevoi and Vagner, 2010). Less frequently, APA occurs
distal to a stop codon in a cryptic intron to generate a truncated
mRNA and protein, with an appended C-terminal sequence
encoded by the intron (Figure S4A) (Di Giammartino et al.,
2011). In mitochondria, a poly(A) tail can be appended to a
30-terminal U or UA to generate a UAA stop codon; however,
unlike PAY*, this mechanism does not generate an alternative
mRNA or protein but instead has evolved to maintain the small
size of the mitochondrial genome by eliminating the 30 UTR (Fig-
ure S4A) (Anderson et al., 1981). APAwithin the coding sequence
of several genes generates truncated transcripts lacking a stop
codon and subjected to exosome-mediated, nonstop mRNA
decay (Frischmeyer et al., 2002; van Hoof et al., 2002). Here,
we show an example of generation of a stable truncated
mRNA by APA within a coding region driven by recoding of an
in-frame Tyr codon to a stop codon, generating a 30-truncated,
30 UTR-less mRNA and a C-terminal truncated protein (Fig-
ure 7A). The absence of any 30 UTR in transcripts generated by
the PAY* mechanism depletes posttranscriptional regulatory
elements, including protein- and microRNA-binding sites (Mayr
and Bartel, 2009). The relatively inefficient generation of EPRSN1
mRNA and protein might be due to suboptimal location of the
polyadenylation elements. About 0.7% of human mRNAs are
predicted to contain APA signal elements within the CDS (Frisch-
meyer et al., 2002). In addition tomyeloid cells, EPRSN1 is consti-
tutively expressed by multiple types of human cells, including
umbilical vein and microvascular endothelial cells, hepatoma-
derived HepG2 cells, embryonic kidney HEK293T cells, and
cervical carcinoma HeLa cells (Figure S4B). Inspection of
EPRS mRNA sequences from several species shows that the
required elements are conserved in primates, e.g., gorilla, chim-
panzee, and macaque, but not in several other mammals, e.g.,
dog, cow, rabbit, pig, andmouse (Figure S4C). Northern analysis
confirmed the absence of a truncated EPRS mRNA in mouse
RAW 264.7 cells (Figure S4D). Thus, PAY*-mediated generationCell 149, 88–100, March 30, 2012 ª2012 Elsevier Inc. 95
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Figure 6. EPRSN1 mRNA Is Generated from EPRS mRNA by the PAY* Mechanism
(A) EPRS mRNA cassette containing upstream (UE) and downstream (DE) APA signal elements and cleavage site (CS).
(B) In vitro cleavage assay for analysis of polyadenylation signal elements. [32P]UTP internal-labeled RNA cassettes from 109 to +131 relative to the cleavage
site, containing the putative APA elements andmutants, were generated by in vitro transcription and subjected to an in vitro cleavage assay in presence of nuclear
extracts from U937 cells.
(C) In vitro polyadenylation of EPRSN1 precleaved RNA. A precleaved, [32P]UTP internal-labeled, 109 nt RNAwas generated from the polyadenylation cassette by
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Figure 7. Schematics of EPRSN1 Generation by
PAY* and Function in Gene Expression
(A) Pathways of EPRSN1 expression by PAY* (left) and
EPRS expression by 30 UTR-based polyadenylation (right).
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upstream of the cleavage sites (underlined) are indicated.
(B) EPRSN1 function in maintaining a translational trickle of
inflammatory gene expression in myeloid cells.
See also Figure S4.of EPRSN1might be a recently evolved, species-selective mech-
anism of gene regulation.
Our results reveal an atypical negative-regulatory mechanism
in which constitutive, low-level expression of a high-affinity
competitor such as EPRSN1 shields a small, constant amount
of GAIT target transcripts from translational repression. The
GAIT complex can be considered as a closed gate that blocks
translation of select transcripts following proinflammatory stimu-
lation by IFN-g, whereas, EPRSN1 can be considered as a ‘‘door-
stop’’ that prevents complete closure of the gate, permitting
a translational trickle of target expression (Figure 7B). The
GAIT target VEGF-A is a potent macrophage-derived angiogenic
factor co-opted by tumors to induce blood vessel development
and facilitate tumor growth and metastasis (Tammela et al.,
2005). Anti-VEGF therapy successfully limits colorectal and renal
cell carcinoma (Kamba and McDonald, 2007); however, adverse
effects of these therapies, including blood vessel regression,(D) In vivo polyadenylation of EPRSN1 APA cassette. U937 cells were transfected with RLuc reporte
cassettes and FLuc reporter plasmid as transfection efficiency control. After 24 hr, luciferase activity
(E) Reduction of EPRSN1 expression diminishes the translational trickle of VEGF-A. U937 cells transf
cleavage site were treated with IFN-g. EPRS and EPRSN1mRNAwere determined by RNA blot with an
linker antibody. VEGF-A and b-actin in cell lysates were determined by immunoblot.
(F) Truncated form of RRM1 mRNA is produced by an in-CDS alternative polyadenylation mechanism
nested RT-PCR using gene-specific primers (GSP). Full-length mRNA expression was determined b
(G) Detection of RRM1N1 mRNA. Total RNA from U937 cells was subjected to RNA blot analysis usi
(H) Truncated mRNA of RRM1 is actively translatable. U937 cell lysates were fractionated by poly
extracted and subjected to northern blot analysis with RRM1 50-specific probe.
(I) Detection of RRM1N1 protein. Western blot was performed with N terminus- and C terminus-spec
See also Figure S3.
Cell 149suggests that VEGF-A is essential for mainte-
nance of healthy vessels as well as for develop-
ment. Moreover, recent studies show that
conditional deletion of macrophage-derived
VEGF-A results in accelerated tumor growth
(Stockmann et al., 2008). We suggest that
a major function of EPRSN1 is to maintain
VEGF-A, and other proinflammatory proteins,
at basal levels required for tissue health and
organismal advantage. The possible function
of RRM1N1 is less clear. RRM1 is the catalyst
of deoxyribonuclotide synthesis during DNA
synthesis and cell division and is the molecular
target of gemcitabine for treatment of cancer
(Jordheim et al., 2011). RRM1N1 contains the
effector binding site and partial catalytic active
site but lacks the C terminus required for high-
affinity binding to its regulated partner RRM2,which conceivably could reduce RRM1 activity or contribute to
gemcitabine resistance. The discovery of multiple potential
PAY* targets, and the validation of RRM1, indicates that PAY*
might be a fundamental mechanism of transcriptome and pro-
teome expansion.
Organisms have evolved multiple mechanisms to compel
low-level or basal amounts of important molecules under condi-
tions in which there is both inductive synthetic pressure as well
as negative regulation to prevent excessive expression. The
most common regulatory mechanisms involve negative-feed-
back loops. For example, the inducible c-fos transcription factor
binds and represses its own promoter, therebymaintaining inter-
mediate levels of the transcription factor and its inducible targets
(Sassone-Corsi et al., 1988). More complex systems involving
multiple feedback loops can also maintain gene expression
within defined limits. As one example, delayed proteasomal
degradation of the bHLH transcription suppressor Hes1 resultsr plasmids containing wild-type and mutant EPRSN1 APA
of cell extracts was determined.
ected with an antisense morpholino oligomer targeting the
ERS-specific probe, and protein by immunoblot with anti-
. Total RNA from U937 cells was subjected to two-round
y RT-PCR.
ng 50- and 30-specific RRM1 probes.
some profiling. The total RNA from various fractions was
ific antibody against RRM1.
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in oscillatory expression of the factor. The oscillation (and
frequency) is established by a pair of temporally displaced
regulatory loops, a feature common to circadian and other oscil-
latory circuits (Hirata et al., 2002). MicroRNAs exert posttran-
scriptional control of gene expression by diverse mechanisms
(Leung and Sharp, 2010). Every microRNA targets multiple
mRNAs, and most mRNAs bind multiple regulatory miRNAs.
The net output is determined by the relative cellular concentra-
tion of the miRNA ensemble and their target mRNAs. Although
individual microRNAs generally inhibit protein production by
small amounts, usually much less than 50%, the sumof targeting
microRNAs can completely switch off gene expression when
and where necessary. In other cases, microRNAs perform
subtle ‘‘tuning’’ functions (Bartel, 2009). For example, atrophin
is repressed by miR-8 in Drosophila but not to the low level
detrimental to cell viability (Karres et al., 2007). The mechanism
by which appropriate microRNA-to-target stoichiometry is
controlled to maintain optimal protein output is not well under-
stood, but negative-feedback loops might be important. For
example, stress-inducible, proinflammatory activation of the
NF-kB transcription in macrophages induces a family of micro-
RNAs that target and repress proinflammatory signaling mole-
cules, including NF-kB (Leung and Sharp, 2010). The timescale
of induction, maturation, and accumulation of these microRNAs
is about 24 hr. This delayed temporal response is suggested to
permit a vigorous inflammatory defense against pathogens while
constraining the response duration to minimize host injury. To
our knowledge, there are not any reports of systems comparable
to the GAIT system in which endogenous, transcript-selective
RNA-binding proteins act as dominant-negative repressors. In
the Pseudomonas RsmA-RsmZ regulatory system, the primary
inhibitor, RsmA, binds the 50 UTR of target mRNAs and inhibits
their translation (Heeb et al., 2002). The secondary regulator,
RsmZ, is a small RNA that acts as an RNA decoy, binding RsmA
and reducing its translational repression activity. This system is
different from the EPRS/EPRSN1 system in which the secondary
regulator, i.e., EPRSN1, binds target mRNAs, not the GAIT
complexprimary inhibitor. Ourmodeling studies show thatmodu-
lation of RsmA by RsmZ will indeed relieve translational repres-
sionbutwill not generate thenonlinear translational trickle charac-
teristic of our newly described mechanism (Figures S1A–S1D).
We propose that the GAIT complex exerts a protective func-
tion as a delayed translational repressor of inflammatory gene
expression, whereas EPRSN1 prevents repression below basal
amounts. Thus, regulation is broadly exerted on a posttranscrip-
tional regulon united by a common structural RNA element.
Importantly, this regulatory mechanism is superimposed on the
identical regulon controlled by the GAIT complex. We envision
the presence of similar regulatory systems that generate
translational trickles of distinct mRNA families. The system
requirements include low-level expression of a fragment of an
RNA-binding protein that binds RNA elements in a posttranscrip-
tional mRNA regulon. The fragment is likely to bind the element
with an affinity substantially higher than the parental RNA-
binding protein. Also, the fragment must be defective with
respect to translational silencing activity, possibly by preventing
holo-complex formation or by direct inactivation of the inhibitory
function. Our results have not yet revealed regulation of EPRSN198 Cell 149, 88–100, March 30, 2012 ª2012 Elsevier Inc.production; however, this is not a necessary system attribute,
and indeed the level of the trickle might be regulated in the
GAIT system (e.g., by condition-dependent regulation of PAY*
activity) and in other systems. The GAIT/EPRSN1 system is
characterized by constitutive, low-level expression of EPRSN1,
established by an intrinsically inefficient PAY* mechanism, and
the absence of any 30 UTR in EPRSN1 contributes to the lack of
regulation. The EPRSN1-driven regulatory system represents
an unusual ‘‘bottom-up’’ mechanism. Instead of the usual
mechanism in which low-level amounts of protein products are
maintained by restricting the inhibitory activity, EPRSN1 exerts
a stimulatory activity that is totally independent of other stimula-
tory or inhibitory activities, including feedback inhibition. In total,
these attributes result in a regulatory mechanism that ensures
a constant, low-level trickle of target protein expression even
under strong negative pressure.
EXPERIMENTAL PROCEDURES
Modeling Procedures
Development and application of dynamic models to simulate the GAIT system
are described in the Extended Experimental Procedures.
Cell Culture
Human U937 monocytic cells (ATCC, Rockville, MD, USA) and primary
human PBM (from healthy clinical donors) were cultured in RPMI 1640medium
containing 10% fetal bovine serum (FBS). For preparation of cytosolic
extracts, the cells were incubated for 1 hr in medium containing 0.5% FBS
and then incubated with IFN-g for an additional 8 or 24 hr.
Plasmids, Site-Directed Mutagenesis, and Recombinant Protein
Expression
EPRSN1 (Met1 to Gln863) was cloned into a pET-28 expression vector between
SacI and SalI restriction sites and expressed as described (Jia et al., 2008).
pcDNA3.1-EPRSN1-c-Myc was generated with pET28-EPRSN1 as template
and cloned between NotI and XbaI restriction sites. The DNA template for
in vitro transcription of EPRSN1 polyadenylation cassette RNA was cloned
into PSP64 vector (PSP64-PAC) between SalI and EcoRI restriction sites.
Specific mutations for EPRSN1 polyadenylation cassette RNAwere introduced
into PSP64-PAC by PCR-based mutagenesis. The reporter plasmids were
constructed by subcloning polyadenylation cassettes into pRL-SV40 reporter
plasmid between XbaI and BamHI sites. The SV40 polyadenylation cassette
was replaced by EPRSN1 polyadenylation cassette.
Immunoprecipitation and Immunodepletion
For immunoprecipitation, cell lysates prepared in phospho-safe extraction
buffer were precleared with protein A/G-agarose beads. After centrifugation,
the supernatants were combined with protein A/G beads and antibody and
incubated with rotation at 4C for 4 hr. The beads were washed with cold
cell lysis buffer. Protein gel loading dye was added and the samples boiled
before gel-loading. For immunodepletion, nuclear extracts from U937 cells
were incubated with rabbit anti-CPSF100 antibody coupled to protein A/G-
agarose beads in extraction buffer. The beads were pelleted, the supernatants
subjected to two additional rounds of depletion, and immunodepletion
established by immunoblot with mouse anti-CPSF100 antibody.
RNA Blot Analysis
For RNA blot analysis, total RNAwas extracted from 108U937 cells using Trizol
reagent. RNA (20 mg) was fractionated on 1% agarose-formaldehyde gel and
transferred to Zeta-Probe GTmembrane. The blot was hybridizedwith random
primer-labeled cDNA probes, and the signal scanned and quantified by Phos-
phoimager. qRT-PCR determinations of VEGF-A, Cp, and GAPDH mRNA
were done with the Taqman Gene Expression Assays for various targets and
the StepOnePlus Real-Time PCR System.
RIP-RT-PCR
Cell lysates were immunoprecipitated with mouse anti-c-Myc antibody or pre-
immune IgG as above. Total and immunoprecipitated RNA were extracted
separately with Trizol reagent, subjected to RT-PCR with Taq DNA poly-
merase, and visualized by 1.5% agarose gel.
Mass Spectrometry
Proteins immunoprecipitated by anti-EPRS linker antibody from U937 cell
lysates were resolved by 4%–20% SDS-PAGE gel. The 95 kDa, Coomassie-
stained band was in-gel digested with trypsin and analyzed by capillary liquid
chromatography tandem mass spectrometry (LC-MS/MS) analysis. CID
spectra were queried against the human reference sequence database using
Mascot software, and matching spectra verified manually and with the Se-
quest and Blast as needed.
G/I Tailing and cDNA Cloning
TotalRNAfromU937cellswasextractedwithTrizol reageatandsubjected toG/I
tailing following the protocol from the Poly(A) Tail-Length Assay Kit. Poly(G/I)-
tailed RNA product was subjected to RT-PCR, and the reaction product loaded
onto a 2.5% agarose TBE gel. The band with lowest molecular weight was
removed, purified, and ligated into pGEM-T vector for DNA sequencing.
Polysome Profiling
Cells were preincubated with cycloheximide (CHX, 100 mg/ml) for 15 min and
washed twicewithCHX-containing coldPBS.Cellswere suspended in TMK lysis
buffer, the lysates were centrifuged, and the supernatant collected. Sucrose
gradient solutions (10% and 50%) containing RNase inhibitor and CHX were
freshly prepared. The cytosolic lysates were loaded on the sucrose gradient,
centrifuged at 29,000 rpm for 4 hr, and subjected to gradient fractionation.
In Vitro Translation
Capped, poly(A)-tailed template mRNAs were prepared with mMESSAGE
mMACHINE SP6 and T7 kits. FLuc-VEGF-A GAIT element-poly(A) and RLuc
reporter RNAs were incubated with U937 cytosolic extract in the presence
of rabbit reticulocyte lysate and [35S]methionine for 90 min at 30C, resolved
by 10% SDS-PAGE gel, and visualized by Phosphorimager.
RNA-Protein Interaction by SPR
Protein binding to CpGAIT-element RNA was determined by SPR in a Biacore
3000 system (Jia et al., 2008). Biotinylated, wild-type, and mutant GAIT-
element RNA (U87C) were separately immobilized on a streptavidin sensor
chip in HBS-P buffer. The analyte flow rate was 5 ml/min in the same buffer con-
taining 5 mM MgCl2. Dissociation constants were calculated for a range of
protein concentrations using Biaevaluation software.
In Vitro Cleavage and Polyadenylation Assays
The polyadenylation cassette RNA was transcribed using a MAXIscript SP6
in vitro transcriptionkit. TranscribedRNAwasdephosphorylatedwithcalf intes-
tinal phosphatase (CIP) at 37C for 30 min, and CIP was removed by phenol/
chloroform extraction. The RNA product was 50-end labeled with 32P-g-ATP
catalyzed by polynucleotide kinase at 37C for 1 hr and purified using a Micro
Bio-Spin 30 chromatography column. To measure cleavage reaction, the
32P-labeled polyadenylation cassette RNA was incubated with U937 nuclear
extract (50%, v/v), KCl (50 mM), MgCl2 (1 mM), EDTA (0.1 mM), glycerol
(10%), DTT (0.2 mM), creatine phosphate (20 mM), and polyvinyl alcohol
(2%). For in vitro polyadenylation assay, 1 mM ATP was added to the same
reaction solution in the presence of precleaved polyadenylation cassette RNA.
Cell Transfection and Dual Luciferase Reporter Assay
U937 cells were transiently cotransfected with 0.5 mg pRL-SV40 plasmid (con-
taining polyadenylation cassette) and 1 mg pCD-FLuc (for normalization of
transfection efficiency) using a human monocyte nucleofector kit. After
24 hr, transfected cells were lysed, and luciferase activity of the lysates was
measured with the Dual Luciferase Reporter assay system. To knock down
endogenous EPRSN1, U937 cells were transfected with morpholino antisense
oligomers or a control morpholino oligomer with a human monocyte nucleo-
fector kit.Global Detection of Candidate PAY* mRNAs
We examined a collection of 19,629 human reference genes (RefGene) in the
University of California at Santa Cruz (UCSC) Genome Browser, including
genomic information on start and stop codon positions and 30 and 50 splice
sites. 30 UTR-less PAY* transcripts were sought using sequence and genomic
alignment information of human ESTs and mRNAs available in the UCSC
Genome Browser. Sequences with tracts (defined as 10 or more contiguous
nt) of poly(A) in the 30 end or poly(T) in the 50 end (for reverse-complemented
ESTs or mRNAs) were identified as poly(A) ESTs or mRNAs. The first A or T
in the poly(A) or poly(T) tract was considered to be the transcript poly(A) site
and is required to be upstream or downstream 5 nt from the nearest alignment
site on the genome. The poly(A) tail of ESTs or mRNAs was required to be
absent (less than 18 A’s within 20 bp downstream or upstream of the poly[A]
site) in the corresponding genome region to eliminate internal priming sites.
When a poly(A)-containing EST or mRNA shared all internal splice sites with
a RefGene, that RefGene was assigned as reference, and the start codon posi-
tion was inferred by the ORF of its RefGene. If the first stop codon coincided
with the start of the poly(A) tail, then the poly(A) sequence was considered
as a 30 UTR-less, in-CDS EST or mRNA. From this group, PAY* candidates
were selected by replacement of TAT or TAC Tyr codons with a TAA stop
codon in 30 UTR-less in-CDS ESTs or mRNAs.Nested RT-PCR for Detecting Candidate mRNAs Generated by PAY*
Total RNA was extracted from U937 cells and subjected to reverse transcrip-
tion using oligo-dT primer. Two-round nested PCR was performed with the
cDNA as template.SUPPLEMENTAL INFORMATION
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